Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients

Solid organ transplant (SOT) recipients receive therapeutic immunosuppression that compromises their immune response to infections and vaccines. For this reason, SOT patients have a high risk of developing severe coronavirus disease 2019 (COVID-19) and an increased risk of death from severe acute re...

Descripción completa

Detalles Bibliográficos
Autores principales: Peter, Lena, Wendering, Désirée Jacqueline, Schlickeiser, Stephan, Hoffmann, Henrike, Noster, Rebecca, Wagner, Dimitrios Laurin, Zarrinrad, Ghazaleh, Münch, Sandra, Picht, Samira, Schulenberg, Sarah, Moradian, Hanieh, Mashreghi, Mir-Farzin, Klein, Oliver, Gossen, Manfred, Roch, Toralf, Babel, Nina, Reinke, Petra, Volk, Hans-Dieter, Amini, Leila, Schmueck-Henneresse, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882037/
https://www.ncbi.nlm.nih.gov/pubmed/35252469
http://dx.doi.org/10.1016/j.omtm.2022.02.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882037/
https://www.ncbi.nlm.nih.gov/pubmed/35252469
http://dx.doi.org/10.1016/j.omtm.2022.02.012

Ejemplares similares